Cargando…
Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer
Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC(50)) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329174/ https://www.ncbi.nlm.nih.gov/pubmed/37426352 http://dx.doi.org/10.1016/j.isci.2023.107116 |
_version_ | 1785069965108314112 |
---|---|
author | Tang, Yuting Wang, Ting Hu, Yaowen Ji, Hongli Yan, Botao Hu, Xiarong Zeng, Yunli Hao, Yifan Xue, Weisong Chen, Zexin Lan, Jianqiang Wang, Yanan Deng, Haijun Deng, Chuxia Wu, Xiufeng Yan, Jun |
author_facet | Tang, Yuting Wang, Ting Hu, Yaowen Ji, Hongli Yan, Botao Hu, Xiarong Zeng, Yunli Hao, Yifan Xue, Weisong Chen, Zexin Lan, Jianqiang Wang, Yanan Deng, Haijun Deng, Chuxia Wu, Xiufeng Yan, Jun |
author_sort | Tang, Yuting |
collection | PubMed |
description | Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC(50)) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC(50) cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy. Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC(50) cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits. |
format | Online Article Text |
id | pubmed-10329174 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-103291742023-07-09 Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer Tang, Yuting Wang, Ting Hu, Yaowen Ji, Hongli Yan, Botao Hu, Xiarong Zeng, Yunli Hao, Yifan Xue, Weisong Chen, Zexin Lan, Jianqiang Wang, Yanan Deng, Haijun Deng, Chuxia Wu, Xiufeng Yan, Jun iScience Article Patient-derived tumor organoids (PDTOs) have the potential to be used to predict the patient response to chemotherapy. However, the cutoff value of the half-maximal inhibition concentration (IC(50)) for PDTO drug sensitivity has not been validated with clinical cohort data. We established PDTOs and performed a drug test in 277 samples from 242 CRC patients who received FOLFOX or XELOX chemotherapy. After follow-up and comparison of the PDTO drug test and final clinical outcome results, the optimal IC(50) cutoff value for PDTO drug sensitivity was 43.26 μmol/L. This PDTO drug test-defined cutoff value could predict patient response with 75.36% sensitivity, 74.68% specificity, and 75% accuracy. Moreover, this value distinguished groups of patients with significant differences in survival benefit. Our study is the first to define the IC(50) cutoff value for the PDTO drug test to effectively distinguish CRC patients with chemosensitivity or nonsensitivity and predict survival benefits. Elsevier 2023-06-13 /pmc/articles/PMC10329174/ /pubmed/37426352 http://dx.doi.org/10.1016/j.isci.2023.107116 Text en © 2023. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Tang, Yuting Wang, Ting Hu, Yaowen Ji, Hongli Yan, Botao Hu, Xiarong Zeng, Yunli Hao, Yifan Xue, Weisong Chen, Zexin Lan, Jianqiang Wang, Yanan Deng, Haijun Deng, Chuxia Wu, Xiufeng Yan, Jun Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
title | Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
title_full | Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
title_fullStr | Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
title_full_unstemmed | Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
title_short | Cutoff value of IC(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
title_sort | cutoff value of ic(50) for drug sensitivity in patient-derived tumor organoids in colorectal cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10329174/ https://www.ncbi.nlm.nih.gov/pubmed/37426352 http://dx.doi.org/10.1016/j.isci.2023.107116 |
work_keys_str_mv | AT tangyuting cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT wangting cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT huyaowen cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT jihongli cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT yanbotao cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT huxiarong cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT zengyunli cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT haoyifan cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT xueweisong cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT chenzexin cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT lanjianqiang cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT wangyanan cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT denghaijun cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT dengchuxia cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT wuxiufeng cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer AT yanjun cutoffvalueofic50fordrugsensitivityinpatientderivedtumororganoidsincolorectalcancer |